Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

NCT02578680 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

616

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab 200 mg
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Pemetrexed
DIETARY_SUPPLEMENT: Folic acid 350-1000 μg
DIETARY_SUPPLEMENT: Vitamin B12 1000 μg
DRUG: Dexamethasone 4 mg
DRUG: Saline solution

Sponsor

Merck Sharp & Dohme LLC